Reports Q3 revenue $452k, consensus $177.56k. “As we approach the end of what has been a productive year of meaningful progress in our mission to ...
Medpage Today on MSN
CAR-T Therapy Leads to Myasthenia Gravis Improvements
BCMA-directed cell therapy can offer a targeted mechanism of action that modulates myasthenia gravis pathology, Vu noted.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback